Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Hungria et al. (Sat,) studied this question.

www.synapsesocial.com/papers/68e669a9b6db6435875f575e — DOI: https://doi.org/10.1056/nejmoa2405090

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Leukemic transformation of polycythemia vera· 2005 · 84 citations
2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma· 2016 · 2,955 citations
3. Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years· 1997 · 291 citations
4. No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)· 2022 · 16 citations
5. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients· 2022 · 16 citations